Nuvectis Pharma Inc NVCT
News
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Nuvectis Pharma To Participate in Upcoming Investor Conferences
